Last updated on November 2018

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Brief description of study

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adults at increased risk for pneumococcal disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX23 when administered 6 months after receipt of either V114 or Prevnar 13. Increased risk for pneumococcal disease is defined as 1) an underlying medical condition, 2) behavioral habits such as smoking, or 3) living in a community/environment with increased risk of disease transmission.

Clinical Study Identifier: NCT03547167

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Paratus Clinical Kippa Pty Ltd - Ring Clinic ( Site 0171)
Brisbane, Australia
  Connect »